

Draft Methods Research Report

Number XX

**Developing and Selecting Topic Nominations for
Systematic Reviews**

Prepared for:

Agency for Healthcare Research and Quality
U.S. Department of Health and Human Services
540 Gaither Road
Rockville, MD 20850
www.ahrq.gov

Contract No.

Prepared by:

Investigators:

**AHRQ Publication No. <xx-EHCxxx>
<Month> 2012**

This report is based on research conducted by the <name> Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. . <###-##-####>). The findings and conclusions in this document are those of the authors, who are responsible for its contents; the findings and conclusions do not necessarily represent the views of AHRQ. Therefore, no statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help health care decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without special permission. Citation of the source is appreciated.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact EffectiveHealthCare@ahrq.hhs.gov.

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.

Suggested citation:

Preface

The Agency for Healthcare Research and Quality (AHRQ), through its Evidence-based Practice Centers (EPCs), sponsors the development of evidence reports and technology assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care in the United States. The reports and assessments provide organizations with comprehensive, science-based information on common, costly medical conditions and new health care technologies and strategies. The EPCs systematically review the relevant scientific literature on topics assigned to them by AHRQ and conduct additional analyses when appropriate prior to developing their reports and assessments.

To improve the scientific rigor of these evidence reports, AHRQ supports empiric research by the EPCs to help understand or improve complex methodologic issues in systematic reviews. These methods research projects are intended to contribute to the research base in and be used to improve the science of systematic reviews. They are not intended to be guidance to the EPC Program, although may be considered by EPCs along with other scientific research when determining EPC Program methods guidance.

AHRQ expects that the EPC evidence reports and technology assessments will inform individual health plans, providers, and purchasers as well as the health care system as a whole by providing important information to help improve health care quality. The reports undergo peer review prior to their release as a final report.

We welcome comments on this Methods Research Project. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to epc@ahrq.hhs.gov.

Carolyn M. Clancy, M.D.
Director
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.
Director, Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.
Director
Evidence-based Practice Program
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Supriya Janakiraman, M.D.
Task Order Officer
Center for Outcomes and Evidence
Agency for Healthcare Research and Quality

Acknowledgments

Peer Reviewers

<Name>

<Place>

<City>, <ST>

<Name>

<Place>

<City>, <ST>

Developing and Selecting Topic Nominations for Systematic Reviews

Abstract

Objectives: The 2009 AHRQ Series Paper 3 described the principles underlying the selection of topics for systematic reviews within the Effective Health Care (EHC) Program. This paper describes methods for topic nomination development to support the selection of topics for systematic reviews within the EHC Program.

Data Sources: The topic nomination development processes described in this paper are derived from 4 years of experience developing, refining, and managing the topic nomination development and selection processes for the EHC Program, along with feedback from Evidence-based Practice Centers and AHRQ staff more recently involved with these activities.

Results: The topic nomination development process includes background searching, definition of the topic scope, a search for systematic reviews, documentation of existing guidance on the topic, a feasibility scan for primary research, and completion of a three part topic brief that includes a Cover Sheet, Selection Criteria document, and Existing Guidance document. Selection of topics for systematic review occurs at monthly meetings of a topic triage group representing stakeholder and scientific perspectives, as well as the programmatic authority vested in AHRQ, and is informed by the information presented in the topic briefs. Results of the topic selection process are described in a Nomination Summary Document to communicate the disposition of nominations to the public.

Conclusions: Potential avenues for expansion of topic nomination development and selection activities within the EHC Program include prioritization among topics selected for a review when resources are constrained and incorporating evaluations of the need to update reviews conducted by the EHC Program into the current topic selection process.

Contents

Developing and Selecting Topic Nominations for Systematic Reviews.....	1
Introduction.....	1
Table 1. EHC Program selection criteria for comparative effectiveness and effectiveness reviews	2
Topic Nomination Development	3
Figure 1. Challenging diversity of topic nominations	3
Figure 2. Nominations by priority condition	4
Topic Nomination Development Team.....	4
Topic Nomination Development Process Overview	5
Table 2. Current priority conditions for the EHC Program.....	5
Figure 3. Topic nomination development and topic selection processes	6
Figure 4. Documents in topic brief	7
Nominations not meeting minimum information requirements.....	7
Background Searching.....	7
Definition of the PICO and Scope	8
Table 3. Poorly- versus well-defined PICOs.....	9
Search for Systematic Reviews.....	10
Existing Guidance Documentation	11
Feasibility Scan	12
Completion of Topic Brief	12
Existing Guidance document.....	12
Selection Criteria document.	13
Cover Sheet.....	13
Table 4. Questions to guide information summarized in Cover Sheet	14
Table 5. AHRQ product lines.....	15
Stakeholder Engagement.....	16
Table 6. Points of stakeholder engagement in topic nomination development.....	16
Efficiency	17
Evaluation of Nominations for New Research	17
Topic Selection	18
Table 7. Potential topic dispositions	18
Topic Selection Results Reporting	19
Future Directions	19
References	21
Glossary.....	22

Developing and Selecting Topic Nominations for Systematic Reviews

Introduction

The Effective Health Care (EHC) Program of the Agency for Healthcare Research and Quality (AHRQ) was created under Section 1013 of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003 to conduct comparative effectiveness research, including comparative effectiveness reviews of scientific evidence on health care interventions. Nominations for comparative effectiveness review topics are received via the EHC Program Web site. Given the extent of health care needs and constraints on the resources available to address these needs, methods to identify the most important topics for synthesized research are essential.

The lifecycle of nominations for comparative effectiveness review topics includes topic identification, topic nomination development, topic selection, and topic refinement (<http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/what-happens-to-my-suggestion-for-research/>). Topic identification is the receipt of nominations for a specific topic that occurs via submissions to the EHC Program Web site or through topic generation activities involving interactions with multiple stakeholders to elicit topics for systematic review. Topic nomination development is the evaluation of a nomination's fit with EHC Program selection criteria. Topic selection is the selection of topics for further development as a systematic review based on the nomination's fit with EHC Program selection criteria. Topic refinement is further scoping of a selected topic, including development of key questions and an analytic framework, to guide the technical conduct of the systematic review. A 2009 AHRQ Series Paper outlined the principles underlying the selection of topics for systematic reviews within the EHC Program.¹ This follow-up paper describes the methods for topic nomination development to support the selection of topics for systematic reviews within the EHC Program. Topic identification and topic refinement are not addressed in this paper.

The initial step in formulating the methodology for topic nomination development involved defining the criteria used to select topics. The 2009 AHRQ Series Paper mentioned above outlined the EHC Program selection criteria against which all nominations are evaluated (see Table 1).¹ Application of these criteria allows selection of topics for research reviews that fit within the mandate and priority conditions of the EHC Program, are important to the U.S. population and health care system, are not already covered by a high-quality review,² represent a large enough evidence base to be feasible for a new review, and have potential for significant clinical impact. The appropriateness criteria are specific to the EHC Program and seek to align selection of topics for systematic review with the overall purpose and mandate of the EHC Program. The other criteria are more generalized and could be applied to the research topic selection activities of other programs, along with the majority of the processes for topic nomination development described below.

Table 1. EHC Program selection criteria for comparative effectiveness and effectiveness reviews

1. Appropriateness	1a. Represents a health care drug, intervention, device, technology, or health care system/setting available (or soon to be available) in the United States
	1b. Relevant to 1013 enrollees (Medicare, Medicaid, S-CHIP, other Federal health care programs)
	1c. Represents one of the priority conditions designated by the Department of Health and Human Services
2. Importance	2a. Represents a significant disease burden; large proportion or priority population
	2b. Is of high public interest; affects health care decisionmaking, outcomes, or costs for a large proportion of the U.S. population or for a priority population in particular
	2c. Was nominated/strongly supported by one or more stakeholder groups
	2d. Represents important uncertainty for decisionmakers
	2e. Incorporates issues around both clinical benefits and potential clinical harms
	2f. Represents important variation in clinical care, or controversy in what constitutes appropriate clinical care
	2g. Represents high costs due to common use, to high unit costs, or to high associated costs to consumers, to patients, to health care systems, or to payers
3. Desirability of New Review / Duplication	3. Would not be redundant (i.e., the proposed topic is not already covered by available or soon-to-be available high-quality systematic review by AHRQ or others)
4. Feasibility	4. Effectively utilizes existing research and knowledge by considering: -Adequacy (type and volume) of research for conducting a systematic review -Newly available evidence (particularly for updates or new technologies)
5. Potential Impact	5a. Potential for significant health impact: -To improve health outcomes -To reduce significant variation in clinical practices known to be related to quality of care -To reduce unnecessary burden on those with health care problems
	5b. Potential for significant economic impact: -To reduce unnecessary or excessive costs
	5c. Potential for change: -The proposed topic exists within a clinical, consumer, or policymaking context that is amenable to evidence-based change -A product from the EHC Program could be an appropriate vehicle
	5d. Potential risk from inaction: -Unintended harms from lack of prioritization of a nominated topic
	5e. Addresses inequities, vulnerable populations (including issues for patient subgroups)
	5f. Addresses a topic that has clear implications for resolving important dilemmas in health and health care decisions made by one or more stakeholder groups


AHRQ – Agency for Healthcare Research and Quality; EHC – Effective Health Care; S-CHIP – State Children’s Health Insurance Program; U.S. – United States

AHRQ staff and Evidence-based Practice Centers (EPCs) conducting topic nomination development were asked to complete an anonymous evaluation of the topic nomination development processes in 2011. There was general agreement among those completing the evaluation that having consistent processes, forms, and criteria that can be used across centers are the most valuable aspects of the current topic nomination development process. EPCs and AHRQ staff noted challenges with the nominations themselves, especially those that are too broad, vague, or ill-suited to the existing process for selecting research reviews (e.g., nominations for new research). The topic nomination development methods described in this paper reflect feedback received from EPCs and AHRQ staff regarding the need for more guidance on these challenging aspects of the process.

Topic Nomination Development


The goal of topic nomination development is to apply a consistent, transparent process for evaluating all nominations against EHC Program selection criteria to inform the selection of topics for systematic reviews. Figure 1 depicts the greatest challenge encountered while developing topics over the past four years – the diversity of topic nominations. Nominations vary greatly in terms of clarity, the nominator’s perspective, clinical condition, and scope. The 429 nominations submitted to the EHC Program from March 2008 to February 2012 represent a wide variety of clinical conditions (Figure 2) and the perspectives of a diverse set of nominators, including patients/consumers, clinicians, researchers, policymakers/payers, professional associations, and industry. The methods for topic nomination development described below have been developed and refined to address this wide variety of nominations and produce the necessary information for all nominations to guide topic selection.

Figure 1. Challenging diversity of topic nominations



PICOTS – populations, interventions, comparators, outcomes, timing, and setting

Figure 2. Nominations by priority condition



ADHD – attention deficit hyperactivity disorder; CVD – cardiovascular disease; DD – developmental delays

Topic Nomination Development Team

Topic nomination development is typically conducted by a small team consisting of a team lead, research associate, librarian, and clinical team member. The team lead is often a doctorate level person with a strong epidemiology, health services research, and systematic review background who provides guidance on the overall content and logic of topic briefs. The research associate is usually a masters level or higher researcher with an epidemiology, biological sciences, or public health background. S/he does the bulk of the work, including the background searching, definition of the topic scope, documentation of the existing guidance, synthesis of the systematic review search and feasibility scan, and evaluation of the topic’s fit with the EHC Program selection criteria. A masters level research librarian conducts the systematic review searches and feasibility scans.

The team should also include a generalist clinical team member with expertise in systematic reviews. This team member dedicates 1-5 hours for each topic nomination answering questions from research associates, consulting clinical specialists, and reviewing topic briefs. This team member helps interpret the nomination and clarifies practice variation, clinical uncertainty, appropriate comparators, important subpopulations and outcomes, and other aspects of the topic necessary to understand the current practice or health policy context underlying the need for synthesized research. Generalist physicians can address many questions, supplemented by specialist input for clinical issues not typically handled in primary care. After completion of the topic brief, it is extremely helpful to ask this clinical team member to review the logical flow of evidence that supports the staff recommendation for the topic’s disposition. Clinical team members can also help identify potential partners for topics.

Topic Nomination Development Process Overview

The topic nomination development process begins with the receipt of a nomination via the EHC Program Web site (<http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/>). The steps in this process are geared towards evaluating how a topic nomination fits the aforementioned EHC Program selection criteria (Table 1). The five main domains of criteria include 1) the appropriateness of a topic, including how it fits within the mandate and priority conditions of the EHC Program (Table 2); 2) the importance to the U.S. population and health care system; 3) feasibility; 4) desirability (or lack of duplication) of a new systematic review; and 5) potential impact of a new research review for the topic. These five domains of the criteria are evaluated hierarchically. If the topic does not meet appropriateness criteria, the other criteria are not considered. Similarly, if a topic meets appropriateness and importance criteria, but is duplicative with an existing review or is not feasible for a new review, the potential impact criteria are not assessed. Evaluating each nomination's fit with these selection criteria using a consistent, transparent process helps ensure that all nominations are treated equitably.


Table 2. Current priority conditions for the EHC Program

<ul style="list-style-type: none">▪ Arthritis and nontraumatic joint disorders▪ Cancer▪ Cardiovascular disease, including stroke and hypertension▪ Dementia, including Alzheimer's Disease▪ Depression and other mental health disorders▪ Developmental delays, attention-deficit hyperactivity disorder, and autism▪ Diabetes mellitus▪ Functional limitations and disability▪ Infectious diseases, including HIV/AIDS▪ Obesity▪ Digestive system conditions, including peptic ulcer disease and dyspepsia▪ Pregnancy, including preterm birth▪ Pulmonary disease/asthma▪ Substance abuse

EHC – Effective Health Care

Figure 3 shows the steps in the topic nomination development process; each step is discussed in detail below. The process is not as linear as this diagram implies; many of the steps in the process are integrated and may occur simultaneously. The process includes background searching, definition of the topic scope, a search for systematic reviews, documentation of existing guidance on the topic, a feasibility scan for primary research, and completion of a three part topic brief comprised of a Cover Sheet, Selection Criteria document, and Existing Guidance document (Figure 4).

Figure 3. Topic nomination development and topic selection processes



The topic brief summarizes information relevant to the topic's evaluation against EHC Program selection criteria.² Consistent organization of this information assists evaluators in undertaking an orderly, efficient consideration of the topic. The Existing Guidance document lists available and in-process research on the topic. The Selection Criteria document is a table detailing how the topic meets or does not meet each of the EHC Program selection criteria in Table 1. The Cover Sheet is seven to eight pages long on average and includes a description of the nomination, background information on the topic, and a summary of the topic's fit with EHC Program selection criteria. Thus, the three main documents are related – the existing guidance on a topic helps determine the topic's fit with the selection criteria, and the topic's fit with the selection criteria is summarized in the Cover Sheet. Supplementary materials, such as summary tables of existing systematic reviews and/or clinical guidelines on the topic, may be included as appendices in the topic brief.

Figure 4. Documents in topic brief




Figure 3 also shows the steps in the topic selection process. Selection of topics for systematic review occurs at monthly meetings of a “topic triage” group representing stakeholder and scientific perspectives, as well as the programmatic authority vested in AHRQ, and is informed by the information presented in the topic briefs. Results of the topic selection process are described in a Nomination Summary Document (described below) to communicate the disposition of nominations to the public.

Nominations not meeting minimum information requirements.

Some nominations to the EHC Program lack sufficient information to evaluate the topic against EHC Program selection criteria so do not undergo topic nomination development. Many of these nominations consist of only a few words or are extremely broad, with no indication of how the nomination could be translated into a feasible topic with a well-defined scope. In such cases, we refer to an established checklist for the minimum amount of information needed to evaluate a nomination. This set of minimum information includes the populations, interventions, comparators, and outcomes of interest to the nominator, as well as the policy and/or clinical context. It is sometimes possible to logically conclude what these parameters are based on the literature and consultation with clinical members of the topic nomination development team so the nomination can go through the topic nomination development process. In other cases, further input from the nominator is necessary, but is not always possible if the nomination was made anonymously or the nominator does not respond to requests for clarification. In addition, the scope of some nominations may be too broad to develop given limited EHC Program resources.

Background Searching

After reviewing the information provided in the topic nomination, topic nomination development begins with a brief background scan to get a firm understanding of the context, clinical practice and health implications of the topic, what tests or treatments are available, the terms and language used to describe the topic, and affected individuals or populations (with attention to health disparities). Suggested sources for this search include PubMed for recent

narrative reviews, clinical library sources (e.g., DynaMed, First Consult, MD Consult, BMJ Clinical Evidence), U.S. FDA Web site, Centers for Disease Control (CDC) and National Center for Health Statistics fast stats for epidemiology and health statistics, National Cancer Institute Physician Data Query, and relevant professional society Web sites. This background information informs the nomination's fit with the appropriateness and importance criteria. This information also aids in the determination of whether the scope of the topic as described in the nomination is clinically appropriate and relevant, and informs development of the preliminary populations, interventions, comparators, and outcomes (PICO) for the topic, which guides the remainder of the topic's development.

Definition of the PICO and Scope

In addition to variation in clinical context and nominator perspective, nominations differ greatly in their scope or level of clarity. A poorly defined PICO can lead to development of a topic that may miss important populations, lack clinical relevance or logic, or is not feasible for a systematic review. During topic nomination development, a number of different sources can be used to further define a topic's PICO, including published literature, clarification from the nominator, and consultation with clinical experts; these sources are used to ensure that the PICO is clinically logical and relevant, representative of the nominator's perspective, includes a realistic set of parameters for a potential review, and would result in a review that is useful to important stakeholders. For the purposes of topic nomination development, the formulation of a PICO is done routinely; timing and setting(s) (PICOTS) may be included if these details are important to the context of the nomination. The literature usually suggests the relevant parameters for a topic, which are compared with the PICO proposed by the nominator. Substantial differences can be reconciled during discussions with the nominator to ensure that the nominator's interests are reflected in the PICO, and consultation with clinical experts can serve to confirm or revise the PICO to be certain that it fits with the current clinical context.

A vague PICO also presents scoping challenges and may lead to a review that is too inclusive or too exclusive. A narrow PICO may reflect proprietary or individual interests that are not broadly generalizable. A broad PICO is often too imprecise for careful consideration, masking important questions or topics for systematic review. There is an inherent tension in the scoping process between fidelity to the original nomination and broadening the scope of the topic to be more relevant to a larger audience. Discussions with the nominator and other important stakeholders serve to ensure that the nominator's interests are clearly articulated in the topic brief along with the evidence needs of other key stakeholders for the topic, such as clinicians or policymakers. For example, a nomination on physical therapy for acute ambulatory conditions was too broad to develop or evaluate against EHC Program selection criteria because the interventions, assessments, and outcomes are heavily dependent upon the specific condition for which there is an indication for physical therapy. The physical therapy literature helped identify the most common conditions for which physical therapy is used. Conversations with the nominator facilitated by a clinical expert in the field of physical therapy clarified that the condition of most interest to the nominator was knee pain secondary to osteoarthritis. Further consultation with the nominator narrowed the nominator's questions to focus on issues such as the relationship between intermediate outcomes and improvement in patient functional performance. On the other hand, a nomination on the effectiveness of a combination of IV diphenhydramine, ketorolac, and metoclopramide in addition to saline intravenous fluids for treating acute migraines in emergency settings was too narrow based on the lack of literature on this drug combination and clinical input. The topic was expanded to more broadly address

interventions for the treatment of acute migraines, thus scoping the topic in a manner suited to a review that would be useful for multiple stakeholders, including patients, clinicians, policymakers, and guideline developers. Another common scoping problem is that children and other relevant subpopulations may be omitted in the nomination.

Determination of the clinical context or clinical logic has also been a challenge. For example, in a nomination on benign prostatic hyperplasia, the nominator was mainly concerned with the use of complementary and alternative medicine for benign prostatic hyperplasia for the reduction of prostate-specific antigen levels. However, prostate-specific antigen levels are not a clinically relevant outcome for the topic. Our workup was revised to reflect relevant outcomes we found in the literature and confirmed by clinical consultation.

During consultations with clinical experts, it is useful to ask questions such as where the nominator’s intervention of interest falls within the usual management of the given condition; what other interventions are potential comparators; what outcomes are clinically meaningful for a given intervention or comparator; and whether the intervention of interest is currently used in clinical practice, and if so how often and in what patient populations is it used most widely.

To aid the topic triage group in making topic selection decisions, a well-defined PICO should include the following—

- Details on the population (e.g., age, sex, disease stage/severity, subpopulations of interest)
- Comprehensive list of interventions and comparators when the nominator has only provided a general category or class
- Definition of usual standard of care if used as a comparator
- List of intermediate and health outcomes, including potential benefits and harms of interventions and comparators, with particular attention to patient-oriented, clinically relevant, and long-term outcomes

Table 3 presents examples of a poorly-defined and a well-defined PICO.

Table 3. Poorly- versus well-defined PICOs

	Poorly-defined PICO: Sleep Apnea	Well-defined PICO: Treatment of Narcolepsy
Population(s):	Adults	Adults (especially young adults) with narcolepsy; subgroups include those with sleep paralysis and/or those with comorbid conditions (e.g., hypertension, arrhythmia, Raynaud's disease)
Intervention(s):	Diagnosis and treatment	Stimulants (e.g., methylphenidate, dextroamphetamine sulfate, dexamphetamine, mazindol (used off-label), methamphetamine, modafinil, armodafinil, sodium oxybate, selegiline); antidepressants (e.g., tri-cyclic antidepressants and SSRIs, venlafaxine, fluoxetine, reboxetine); behavioral interventions (e.g., sleep and nap schedules, avoidance of stimulants such as caffeine); and/or alternative therapies (e.g., light therapy)
Comparator(s):	Current diagnosis and treatment alternatives	Above interventions alone or in combination
Outcome(s):	Standard for diagnosis	Benefits: improvements in daytime sleepiness and sleep paralysis; return to normal functioning (e.g., ability to drive, work, and maintain social relationships) Harms: cardiovascular abnormalities (e.g., hypertension and arrhythmia) and headache

PICO – populations, interventions, comparators, and outcomes; SSRIs – selective serotonin reuptake inhibitors

Search for Systematic Reviews

Searching for literature to answer the nominator's question is usually conducted in a sequential manner, beginning with synthesized literature identified from a formal search of medical literature databases, then research products and activities identified from searches of specific organization and agency Web sites described below under Existing Guidance Documentation, and later moving to formal searches for trials and other study designs as described below under Feasibility Scan.

Searching begins with identification of existing and in-process systematic reviews and meta-analyses. This search is conducted by a librarian, but it is helpful to provide the librarian with a list of suggested search terms, including Medical Subject Headings (MeSH) and key words, based on the initial background scan, as well as the databases to search (e.g., MEDLINE, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL)) and citations that are good illustrations of the topic (e.g., high-quality narrative or systematic review identified in initial background scan). The search strategies for existing systematic reviews are a good starting point for development of this search. Based on prior experience, a search for synthesized literature over the past 5 years is often sufficient, although a search of the past 10 years is necessary for some topics, such as those related to well-established interventions that have not been the focus of recent research activity or topics with limited existing research. In some cases, search dates are dependent upon when the technology or intervention was first developed.

After receiving synthesized literature search results from the librarian and reviewing relevant abstracts, an iterative process begins to determine if the search for synthesized research is adequate and captured the questions raised in the nomination or needs to be narrowed or refined. Citations for the most recent, relevant systematic reviews should be listed in the Existing Guidance document, including the search dates, methods, and overall fit with the nomination.

The ultimate goal of this step is evaluation of the duplication selection criterion. In order that EHC Program resources are put to the best use, the EHC Program may decide not to pursue systematic reviews on topics that are already addressed by existing or in-process high-quality reviews. Such a decision does not constitute endorsement of non-AHRQ systematic reviews, but rather the recognition that there are many important topics in health care that would benefit from systematic evidence reviews and only limited resources with which to do those reviews. The EHC Program may consider a topic as adequately covered by a recent review performed or commissioned by a U.S. government agency (e.g., AHRQ, USPSTF, NIH, VA, CDC) or an independent center, academic institution, or government (e.g., Cochrane Collaboration, NICE, Canadian Agency for Drugs and Technologies in Health (CADTH), other center or independent group) using acceptable methodology for evidence grading and conflict of interest management. In some cases, the EHC Program may decide to undertake a review despite possible duplication for reasons such as—

- A U.S. government product is needed for development of guidelines, policy, or translational products for patients or clinicians.
- Impact will be ensured by use of the AHRQ dissemination infrastructure.
- There are potential benefits from expanding or revising the methodology or better managing conflict of interest in the existing review.
- The existing review was conducted in another country where practice patterns or epidemiology are significantly different than what would be found in the United States or conclusions are not consistent with U.S. guidelines.

- Current clinical practice diverges from consistent conclusions from recent systematic reviews.
- Existing systematic reviews have conflicting conclusions.
- The nominator confirms that current reviews do not meet stated needs.

Existing Guidance Documentation

This step focuses on searching for available and in-process research (e.g., reviews, guidelines, studies) and activities (e.g., CMS policies, NIH conferences) related to the topic, which is recorded in the Existing Guidance document along with the results of the more formal librarian searches for systematic reviews (described above) and primary studies (described below under Feasibility Scan). The existing guidance informs the evaluation of the topic's fit with some of the EHC Program selection criteria, such as duplication, feasibility, and potential impact. Documentation of existing guidance on the topic typically begins while the librarian is conducting the search for systematic reviews. The sources searched for existing guidance include—

- In-process and completed AHRQ products
 - Evidence reviews (from Evidence-based Practice Center (EPC) and EHC Programs)
 - Technology assessments
 - U.S. Preventive Services Task Force (USPSTF) recommendations
 - Developing Evidence to Inform Decisions about Effectiveness (DEcIDE) Network projects
 - Translational products (e.g., patient and clinician guides)
- National Institute for Health and Clinical Excellence (NICE) guidelines
- Cochrane Collaboration reviews and protocols
- Drug Effectiveness Review Project (DERP) drug class reviews
- Health technology assessments (HTAs) (from Centre for Reviews and Dissemination (CRD) database, which includes content from the International Network of Agencies for Health Technology Assessment (INAHTA) and 20 other HTA organizations)
- Veterans Administration (VA) products (technology assessments from the VA Technology Assessment Program, systematic reviews from the Evidence Synthesis Program, and VA/Department of Defense Clinical Practice Guidelines)
- National Institutes of Health (NIH) consensus statements and upcoming conferences
- CDC Guide to Community Preventive Services publications and recommendations for public health topics
- Centers for Medicare & Medicaid Services (CMS) policies and coverage updates
- Clinicaltrials.gov for active, recently completed, or recruiting studies
- National Guideline Clearinghouse at guidelines.gov and other searches (e.g., PubMed) for clinical practice guidelines

In order to show the breadth of existing or in-process AHRQ activities in the clinical domain, AHRQ products that are related to but don't directly overlap with the nomination should be documented. For example, there may not be any AHRQ products addressing a nomination for CAM therapies for sleep apnea, but all AHRQ products on sleep apnea should be documented. A comprehensive list of related AHRQ products can also serve as a reference of those who have worked on similar topics and could potentially serve as experts during later stages of the topic nomination development, refinement, or review process. It is also helpful to document the key

questions for all relevant AHRQ reviews to illustrate whether the full scope of the nomination is addressed by the review.

Feasibility Scan

After the search for systematic reviews, a search for controlled trials is conducted by the librarian to determine the feasibility of a new review on the topic. The dates for this scan can begin from the last search date of the most recent high-quality systematic review. The results of the feasibility scan will show whether the most recent systematic review fully covers the topic. If there are landmark studies or a significant number of studies that have not been captured in the most recent systematic review, the need for a new review on the subject should be considered. The recent introduction of new interventions or technologies for which there is published evidence may also underscore the need for a review on the topic. In the absence of a recent high-quality systematic review, a feasibility scan of the last 5 or 10 years will be needed to determine the adequacy, type, and volume of primary research recently published on the topic that would be available for a review. For those topics with a very limited literature base, a search may need to be completed without date limits. If very few controlled trials are found or for topics that are not appropriate for controlled trials, the feasibility scan should be expanded to include study designs such as case series, case-control, before-after, cohort, and other observational designs. The sufficiency of available studies to warrant a review will partly depend on the topic. For topics where controlled trials are possible but only observational studies are available, a review may not have significant clinical impact until there is higher quality evidence on the topic. For other topics, such as those focused on potential harms, data from observational studies may be sufficient for a review.

Synthesis of the feasibility scan results is limited to a summary of the number of relevant studies available for inclusion in a review and documentation of any landmark studies. Unlike synthesis of the results of searches for primary research conducted during a systematic review, synthesis of feasibility scan findings during topic nomination development does not include quality rating of articles or an assessment of the results of the studies. The aim is only to provide a sense of the volume of the available literature that could potentially be included in a review. High volume or very broad feasibility scan results are a challenge for some nominations. These cases require organization of the results by the most important parameters of the particular topic, such as setting, population, outcomes, comparators, study design, or length of followup, to aid in the determination of whether the existing literature covers all aspects of the nomination. For example, the feasibility scan results for a topic on fibromyalgia treatment were categorized by the type of intervention studied, including pharmacological, psychological, exercise, and CAM therapies, and for a topic on seasonal allergy treatments they were divided by studies addressing adults versus children.

Completion of Topic Brief

Existing Guidance document.

At this point, the Existing Guidance document should be completed. All available and in-process research identified from the search for systematic reviews, feasibility scan, and searches of specific organization and agency Web sites described above under Existing Guidance Documentation should be listed in the Existing Guidance document.

Selection Criteria document.

Details of how the topic meets or does not meet each of the EHC Program selection criteria should be recorded in the Selection Criteria document. The appropriateness and importance criteria are informed by background searching on the topic, the duplication criterion is determined by the results of the search for systematic reviews, and the feasibility criterion is based on the results of the feasibility scan for primary research. The potential impact of a new review on the topic is the last set of criteria considered. The potential of a new review to have significant health impact is influenced by the amount of clinical uncertainty and practice variation surrounding the topic. The need for translational products geared toward patients, clinicians, and policymakers also affects the potential for impact from the review. If recent high-quality reviews and/or practice guidelines exist, the added value of an AHRQ review on the topic should be addressed.

Cover Sheet.

The Cover Sheet includes a description of the nomination, comprising a summary of the nominator's interests, the staff-generated or nominator-provided PICO, the policy or clinical context of the nomination, and any key questions provided by the nominator. A section on key considerations and points for discussion contains the following information—

- Summary of nomination's fit with appropriateness and importance criteria
- Disease burden
- Description of the condition
- List of relevant drugs, devices, therapies, and technologies
- Clinical logic of the nominator's PICO
- Reason for any changes to the scope of the original nomination
- Clinical uncertainty and practice variation
- The most recent, relevant clinical practice guidelines on the topic, including a summary of conflicting recommendations, areas lacking sufficient evidence for a recommendation, and whether the guidelines are based on a systematic review
- Existing high-quality systematic reviews beginning with AHRQ products, including the number of studies included and a statement of whether the reviews agree or disagree in their conclusions
- How the topic is or is not covered by existing work
- Results of the feasibility scan, including the number of in-process studies identified on clinicaltrials.gov to give a full picture of how much literature would be available for a new review and if the topic represents an active area of ongoing research
- Related IOM comparative effectiveness research priorities³
- Suggestions for individuals and organizations to consult if the topic is voted forward for a review or other EHC Program product
- Concluding bullet on rationale for staff recommendation on topic's disposition, including assessment of the potential impact of a new research review if applicable

Key points and considerations in the Cover Sheet should have a logical flow leading to the staff recommendation for the disposition of the topic (described further below). If there are multiple relevant categories within the nomination (e.g., diagnosis and treatment, subpopulations such as children and adults), the topic brief should be clearly divided into sections with subheadings that identify each area of the nomination. Table 4 lists questions that should be considered when summarizing information on the topic in the Cover Sheet. This list is divided

into questions relating to the PICO, the nominator, clinical practice, existing literature and feasibility, impact, and program/product fit.

Table 4. Questions to guide information summarized in Cover Sheet

PICO-Related Questions	<ol style="list-style-type: none"> 1. What are the definitions of terms used in the nomination? 2. If the scope of the original nomination is too broad, can we narrow the scope to a clinically relevant topic useful to the nominator? 3. Are there appropriate and clinically relevant subgroups? 4. Is the nominator-defined PICO clinically relevant? 5. Does the question address comparative effectiveness or clinical effectiveness?
Nominator-Related Questions	<ol style="list-style-type: none"> 6. What is the underlying motivation for this nomination? 7. What are the needs (e.g., personal, clinical, policy) of the nominator? 8. Is the nominator aware of existing AHRQ products?
Clinical Practice Questions	<ol style="list-style-type: none"> 9. What are the potential clinical harms of this intervention? 10. Is this product used off-label for indications? 11. What is the current utilization of the intervention of interest? 12. What is current medical practice and does variation exist?
Existing Literature/Feasibility Questions	<ol style="list-style-type: none"> 13. Are there any existing or in-process AHRQ products related to the topic? If so, how does it impact the topic? <ol style="list-style-type: none"> a. Are there additional data that would warrant an update to an existing AHRQ systematic review? b. If suggesting an update to or expansion of an existing AHRQ report, what key questions should be updated or expanded upon? 14. How do existing systematic reviews impact current clinical practice (e.g., widely used, available, publicly accessible)? 15. Is the existing work of high quality and does it use rigorous systematic review methods? 16. Do existing systematic reviews address comparative effectiveness? 17. How well are clinically relevant subgroups represented in existing literature? 18. What are the definitions for interventions/comparators in existing reviews and are these standardized? 19. Is the topic feasible for a full research review? <ol style="list-style-type: none"> a. How many studies have been published since the most recent high-quality review? b. What type of data is available (e.g., RCTs, case studies)? c. Are there landmark trials published since the last systematic review? 20. Does the topic warrant inclusion of other study types, such as observational studies, due to the nature of the research question or the importance of harms or long-term outcomes? 21. Are there any large ongoing trials that would impact the timing of a review on the topic?
Impact Questions	<ol style="list-style-type: none"> 22. What is the prevalence/burden of disease? 23. What would be the impact of a new review? 24. What guidelines currently exist in this area? 25. Would a new report be used to create updated guidelines or policy decisions? 26. Would a new report likely have a different outcome than existing reports? 27. What stakeholder group(s) is the topic relevant to? 28. Who will use a potential research review? 29. Are other groups currently working on similar projects or reviews?
Program/Product Fit Questions	<ol style="list-style-type: none"> 30. Are there gaps that could be filled by new research? <ol style="list-style-type: none"> a. Could this research be addressed by the DEcIDE network or other existing AHRQ resources? 31. Does this question address broader issues than comparative effectiveness (e.g., natural history, cost, access) that would make it more appropriate for a generalist review? 32. Would this topic be more appropriate for another product such as a technical brief? 33. Would the topic be best suited for programs outside of AHRQ? 34. Is it appropriate to break this topic up into multiple reviews? 35. Is there a role for the topic refinement process to further narrow the topic? 36. Does the nomination represent a translation or dissemination need (e.g., lack of consumer-focused guidance)?

AHRQ – Agency for Healthcare Research and Quality; DEcIDE – Developing Evidence to Inform Decisions about Effectiveness; PICO – populations, interventions, comparators, and outcomes; RCT – randomized controlled trial

The final step in completing the topic brief is assigning a staff recommendation for the disposition of the nomination based on its fit with the EHC Program selection criteria, which is voted on by a topic triage group during topic selection (see below). For nominations with multiple aspects addressed in the topic brief (e.g., diagnosis and treatment), it is often necessary to assign separate recommended dispositions for each aspect of the topic. A topic's disposition may reflect the fact that it does not meet appropriateness or importance criteria, is already covered by an existing review, or is not feasible for a new review. For some topics, ongoing research or activities may be underway that impact the timing for developing the topic. For example, there may be large, in-process clinical trials whose results will heavily influence any conclusion from a systematic review. In such cases, the Cover Sheet should include details on what the ongoing activity is, how it will affect the topic's disposition, and the date when the results are expected to be available so the topic can be reconsidered at that time.

There are a number of different AHRQ products for which topics may be selected, including a technical brief, comparative effectiveness or effectiveness review, or update to an existing AHRQ review. The context and purpose of each of these products is described in Table 5. In addition to these products, topics are sometimes recommended for other activities, such as referral to the team conducting an in-process review on the topic to be considered for inclusion in the review's scope, for refinement as a review of reviews, or for a potential methods project. When the topic brief is completed, its contents should be discussed with members of the topic nomination development team who have clinical expertise to ensure that the staff recommendation for the topic's disposition is clinically logical.

Table 5. AHRQ product lines

<p>Technical Brief</p>	<p>Technical briefs lay out a framework for understanding important issues and map the evidence for emerging or contentious topics where a systematic review that synthesizes and grades the evidence is unlikely to move the field forward. Technical briefs do not grade the evidence or present conclusions about efficacy, although they do document whether the existing evidence base is inadequate to support a conclusion and why. A technical brief is appropriate for two different scenarios:</p> <p>1) A technology for which research to date is clearly insufficient to draw any firm conclusions about efficacy, but which raises a lot of questions about how it should be used, who it should be used for, how it should be evaluated, or other contextual questions. These are often emerging technologies that are diffusing rapidly, although they may be older technologies that have never been adequately studied. An example would be positional MRI, which is a collection of related devices being aggressively marketed based on claims about effectiveness but without any RCT outcome data. The purpose is to create a quick snapshot of where the evidence is or is not, and identify the questions that should be asked. Documentation in the Cover Sheet should include the lack of enough evidence for a synthesis to be useful and how a technical brief could be used to influence research, diffusion, etc.</p> <p>2) Interventions for which a lot of research is available but there is confusion about how to organize what is known. The purpose of this kind of technical brief is to document what is available and create a framework and next steps for either new research or full systematic reviews. An example would be wheelchair assessment, which has been around for a long time and there are many guidelines and studies, but no conclusions. Be sure to document that a) there is too much confusion in the field about definitions and outcomes for a synthesis to be useful, and b) how the resulting technical brief could be used to influence research/diffusion/etc.</p>
<p>Comparative Effectiveness or Effectiveness Review</p>	<p>Comparative effectiveness and effectiveness reviews focuses on topics that pose a decisional dilemma for stakeholders, such as an available intervention that has considerable equipoise about the appropriateness of use. These reviews include relevant comparisons and assess important patient-centered outcomes (both safety and effectiveness).</p>

Update Review	An update review focuses on the original questions of a previously completed research review. Indicators of the need for an update of a previous AHRQ review can include new evidence of harm, a new intervention for comparison, or a large new trial with differing results than the previous review's conclusion. A limited update may focus on a specific sub-population, comparison, or outcome/harm. If new key questions are warranted in an update of a previous review, the scope of the nomination may be deemed different enough from an existing AHRQ review to warrant a "new" review instead of an update.
----------------------	--

AHRQ – Agency for Healthcare Research and Quality; MRI – magnetic resonance imaging; RCT – randomized controlled trial

Stakeholder Engagement

Table 6 shows the points of stakeholder engagement during topic nomination development. In this context, stakeholders are defined as clinicians, policy makers, guideline developers, professional societies, consumers, and patients; the individual nominator may represent one or more of these stakeholder groups. Input from nominators is sometimes needed to clarify the population, interventions, or outcomes of interest when the nomination includes a broad scope or less-defined PICO. As mentioned above, discussions with local, regional, or national clinical experts are often necessary to appropriately scope a topic at the beginning of topic nomination development, and these discussions occur at the discretion of the topic nomination development team. Experts are generally identified by the clinical team member, who communicates with these experts via email or phone. Less frequently, feedback from the individual nominator may be required. EHC Program staff may provide guidance to the topic nomination development team as to whether and when the nominator, policymakers, or professional society representatives should be consulted. If a topic is deemed duplicative with in-process or existing reviews or programmatic activities, it is sometimes important to verify that the existing products meet the nominator's needs. This can occur before the topic is presented to the topic triage group, after presentation to the topic triage group but before final disposition of the topic, or during topic refinement, and EHC Program staff usually determine the appropriate time for this engagement with the nominator.

Stakeholder input can often be solicited via email, although longer conversations are sometimes required that are better handled on the phone after an initial request for information over email. More formal telephone conferences facilitated by clinical team members are occasionally appropriate to clarify nominations from professional societies or policymakers. For topics voted forward for a systematic review, it can be useful to establish a partnership with a group that will develop clinical practice guidelines based on the review to ensure clinical impact and facilitate dissemination. In such cases, communication with the partnering organization is essential to ensure that the timing of the review's completion is coordinated with guideline development.

Table 6. Points of stakeholder engagement in topic nomination development

Stage of Topic Nomination Development	Type of Stakeholder	Purpose
Early scoping of topic, before searches performed	Nominator	Clarification of topic scope and PICO
	Clinical experts	Interpretation of nomination, confirmation of clinical relevance of topic scope and PICO
Either during topic nomination development or topic refinement	Nominator	Verification that existing review(s) meet their needs
	Health care professional organization	Establish partnership for development of guidelines based on AHRQ review

AHRQ – Agency for Healthcare Research and Quality; PICO – populations, interventions, comparators, and outcomes

Efficiency

The need for and importance of topic nomination development in identifying the most important topics for systematic review is unquestionable. But allowing a longer timeline for in-depth topic nomination development comes at the expense of extending the time between submission of nominations and their disposition. Ultimately, the timeline for completion of any commissioned reviews and translational products or clinical practice guidelines produced from the reviews is lengthened. Topic nomination development for the EHC Program is time intensive because a universal perspective is required given the public funding for products that could be important to several segments of the population. As mentioned above, nominations to the EHC Program cover a broad range of clinical conditions and are submitted by a wide array of stakeholders with varying perspectives and needs. Thus, a significant amount of effort is required to find a clear context for each topic. The time needed to complete the steps in the current topic nomination development process varies considerably depending on the complexity and breadth of the topic nomination, with the total time for completion of a topic brief ranging from 16 to 68 hours. This estimate does not include time needed for feedback loops such as going back to the nominator for clarification or getting expert feedback. The EHC Program receives an average of 9 nominations per month. Eight nominations on average are triaged per month, and the mean time from nomination submission to triage is 7 months. Balancing efficiency with the need for a comprehensive, effective process will continue to be a challenge and will require exploration of potential process revisions, such as instituting a streamlined process for nominations that are clearly covered by existing programmatic activities (e.g., in-process EHC Program reviews, USPSTF recommendations).

Evaluation of Nominations for New Research

Another challenge encountered in topic nomination development for the EHC Program is presented by nominations for new primary research, which are ill-suited to the existing process for selecting topics for research reviews. In 2011, the Scientific Resource Center and AHRQ responded to this challenge by adapting the EHC Program's process for evaluation of topics for systematic review to identify topics appropriate for potential new research due to a significant research gap that is important to clinician, policymaker, and/or patient decisionmaking. In this process, research gaps and the potential impact of new research on clinical practice and policy are identified by examining—

- Systematic reviews and editorials for any discussion of research gaps
- Clinical practice guidelines for areas reported as having insufficient evidence to make a recommendation
- Recently published studies to determine to what extent research gaps have been filled
- In-process studies and newly funded Federal research or funding opportunities to get a sense of whether it is an active area of research
- Coverage determinations that provide a perspective on uncertainty surrounding a topic

Clinical consultation is used to confirm a lack of evidence and the need to rely solely on clinical judgment. This background information on the need for new research on a topic is included in the Nomination Summary Document that is sent to the nominator and posted on the EHC Program Web site (see below). Evidence generation programs at AHRQ, such as the DEcIDE Network, as well as researchers, funders, and programs outside of AHRQ, can access this information to support their primary research agendas.

Topic Selection

Selection of topics for further development as a research review occurs during monthly “topic triage” meetings that last approximately 2 hours. During each meeting, approximately eight to nine nominations, supported by topic briefs, are presented to a topic triage group consisting of members from various components of the EHC Program and AHRQ. These members represent stakeholder and scientific perspectives, as well as the programmatic authority vested in AHRQ. At the beginning of each topic triage meeting, voting members are asked to disclose any potential financial, business, professional, or intellectual conflicts of interest related to any of the topics that will be discussed and voted on during that meeting, using a guide to determining potential conflicts of interest that is included in the meeting materials. Members disclosing potential conflicts of interest are asked to abstain from voting on the relevant topic(s) and in some cases may recuse themselves from any discussion on the topic.

The topic briefs are distributed to the topic triage group 5 days in advance of each meeting to allow voting members time to read the supporting materials for each topic before the meeting. During the meeting, a brief, 3-5 minute presentation of the topic is made by a member of the topic nomination development team and is limited to the most significant points from the topic brief that provide a clear rationale for the staff recommended disposition of the topic. The staff recommendation(s) serves as a jumping off point for the discussion during the topic triage meeting and may be revised during the course of the meeting. Following the presentation, the meeting facilitator invites a 5-10 minute discussion from the voting members of the topic triage group. This discussion is an opportunity to clarify points about the topic and allow participants to raise any issues which might be relevant to the disposition of the topic. Most of the questions regarding the brief are answered by the presenter or a clinical expert (if available), while some questions are posed to the group. At the end of the discussion, the facilitator summarizes the comments and suggestions made during the discussion and the original or revised staff recommendation for the topic’s disposition. Table 7 shows the potential dispositions that can be recommended for topics.

Table 7. Potential topic dispositions

- | |
|---|
| <ul style="list-style-type: none">▪ Topic is outside the purview of the EHC Program and does not meet EHC Program appropriateness criteria▪ Topic is already addressed by existing research review(s) or programmatic activities▪ Topic is important, but current research is too limited for appropriate program product development▪ Topic should be tabled because ongoing research or activities are underway that impact the timing for determining the topic’s disposition▪ Topic will return to a future topic triage meeting with more information that is necessary to determine the topic’s disposition, such as nominator or stakeholder feedback▪ Topic will go forward for further refinement as a systematic review or technical brief▪ Topic will be considered for potential new primary research |
|---|

The facilitator then polls all members for a vote on the recommended disposition of the topic. Group members are asked to indicate their enthusiasm for the recommended action on a scale of 1 to 5 (1 = no enthusiasm, 3 = neutral, 5 = complete enthusiasm). Any member with a vote less than 3 is given the opportunity to briefly present his/her perspective at the time of the vote. Members with a vote of 3 or higher may choose to add advisory comments (e.g., Key Informants to consider for topic refinement). Recommendations with an average vote of less than 3 result in further discussion to arrive at an alternate disposition for another vote. These recommendations

are not binding, but are highly weighted in the final decision by AHRQ as to the research topics selected for further development as a research review within the EHC Program.

Topic Selection Results Reporting

Transparency is an important aspect of the topic nomination development and selection processes. General information about the topic nomination development and selection processes is available on the EHC Program public Web site, including health-care service and patient population priorities, priority conditions, and the EHC Program selection criteria (<http://effectivehealthcare.ahrq.gov/index.cfm/submit-a-suggestion-for-research/how-are-research-topics-chosen/>). All nominations submitted to the EHC Program are also posted on the public Web site. In addition, decisions regarding whether a nomination is selected for a systematic review are briefly summarized in a one to three page Nomination Summary Document. This document is completed for all nominations and is sent to the nominator and posted on the EHC Program public Web site. This document includes the following—

- Results of topic selection process and next steps
 - Summary of disposition of topic (e.g., topic does not meet EHC Program appropriateness criteria, topic is covered by an existing research review or programmatic activities, topic is not feasible for a systematic review, topic will go forward for refinement as a new or updated systematic review)
 - For all reports that are considered as addressing the topic, a full citation, with a link to the report if publically available
 - For topics that are addressed by in-process AHRQ reports, a link to sign up for notification when relevant in-process AHRQ reports are posted
 - For topics going forward as a systematic review, a statement that the final scope of a review may change during topic refinement, and a link to sign up for notification when key questions are posted for public comment
- Topic description
 - Nominator identified by category only (e.g., individual, health care professional association, public payer, organization)
 - Nomination summary, including PICO
 - Key questions provided by the nominator
- Considerations
 - How topic fits with EHC Program selection criteria, with link to all criteria
 - Rationale for topic disposition (e.g., why topic does not meet selection criteria, how a topic is covered by existing review(s), summary of insufficient evidence to address topic, importance and potential impact of topics going forward as a systematic review)
 - Key questions or inclusion criteria for all reports that are considered as addressing the topic

Future Directions

Several potential avenues for expansion of topic nomination development and selection activities within the EHC Program exist. The EHC Program continues to work with stakeholders to identify issues of high interest to the general public, areas where evidence gaps hinder high-quality care, and topics where systematic review might clarify care for high-priority populations. This stakeholder engagement in topic identification often results in a number of topics in a single

clinical domain that have been given a high priority for systematic review by a diverse set of stakeholders. The number of topics voted forward for a research review within the EHC Program is likely to grow significantly, making it necessary to go beyond selection of topics to prioritization of the topics expected to have the highest clinical impact.

Another possibility is exploring the potential of incorporating a value of information (VOI) analysis as a sequential step after topic selection to prioritize amongst topics voted forward by the topic triage group.⁴ VOI may also be considered for prioritizing amongst multiple research topics addressing a single clinical condition identified in topic identification projects, or for assessing the need for new primary research. This quantitative approach includes a conceptual VOI analysis that considers data, some of which could be taken from the topic brief, including the number of patients that might potentially be affected by a new research review on the topic; the distribution of possible health outcomes, costs, and net benefits of alternative health interventions; reduction in uncertainty from a new review; the likelihood that a review would change clinical practice; and the durability of a review's relevance. One unresolved difficulty in applying a VOI analysis would be in determining relative value across the breadth of topics that are selected to go forward, including 13 priority conditions, multiple subgroups (e.g., adults, children, minorities, acute, chronic), and a range of stakeholder perspectives.

Another potential revision to the current topic nomination development process is inclusion of information about how a nomination relates to the national priorities for comparative effectiveness research outlined by the Patient-Centered Outcomes Research Institute (PCORI). Finally, the EHC Program will soon incorporate evaluations of the need to update reviews conducted by the EHC Program into the current topic selection process.

Transparency of the topic selection process will soon be further enhanced by the posting of Cover Sheets and Existing Guidance documents on the EHC Program public Web site. Because these documents will be available to the public, consistency across topics in the information presented will be especially important. If the EHC Program implements a prioritization process for selected topics, clear communication of prioritization decisions to the public will need to be considered.

References

1. Whitlock EP, Lopez SA, Chang S, et al. Identifying, selecting, and refining topics. In: Agency for Healthcare Research and Quality. Methods Guide for Comparative Effectiveness Reviews. Rockville, MD: 2008. PMID: 21433404.
2. Institute of Medicine. Finding what works in health care: standards for systematic reviews. Washington, DC: National Academies Press; 2011. PMID: None.
3. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: The National Academies Press; 2009. PMID: None.
4. Meltzer, DO, Hoomans, T, Chung, JW, et al. Minimal modeling approaches to value of information analysis for health research. Methods future research needs. Report No. 6. (Prepared by the University of Chicago Medical Center and the Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-Based Practice Center under Contract No. 29007-10058.) AHRQ Publication No. 11-EHC062-EF. Rockville, MD: Agency for Healthcare Research and Quality; 2011. PMID: 21977528.

Glossary

Comparative effectiveness and effectiveness reviews - research reviews that outline the effectiveness — or benefits and harms — of treatment options.

Feasibility scan - a brief search for primary studies to evaluate the sufficiency of available evidence to warrant a new review on the topic.

PICO - populations, interventions, comparators, and outcomes.

PICOTS - populations, interventions, comparators, outcomes, timing, and setting.

Technical brief - a research review that explains what is known and what is not known about new or emerging health care tests or treatments.

Topic brief - a summarization of information obtained as a result of the topic nomination development process consisting of the Cover Sheet, Selection Criteria document, and Existing Guidance document.

Topic identification - receipt of nominations for a specific topic by the EHC Program.

Topic nomination - topic suggestion from individual or group for a comparative or clinical effectiveness research review.

Topic nomination development - evaluation of a nomination's fit with EHC Program selection criteria using a process that includes background searching, definition of the topic's scope, a search for systematic reviews, documentation of existing guidance on the topic, a feasibility scan for primary research, and completion of a three part topic brief.

Topic prioritization - relative ranking of topics according to the expected level of clinical impact from a review.

Topic refinement - following topic selection, further scoping of a topic in response to input from key stakeholders and technical experts that culminates in the development of key questions and an analytic framework to guide the technical conduct of the review and define the targeted patient populations, interventions, comparators, outcomes, timing, and clinical settings.

Topic selection - selection of topics for further development as a research review.

Topic triage group - a group representing stakeholder and scientific perspectives, as well as the programmatic authority vested in AHRQ, which selects topics for further development as a research review.

Topic triage meeting - monthly meeting during which topics are selected for further development as a research review.

Update review – a research review that focuses on the original questions of a previously completed AHRQ research review.